CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 651 enrolled
Drug / intervention
Leuprorelin acetatedrug
Likely dose
Leuprorelin acetate 11.25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02154139
NCT02154139N/ACompleted
CompareCT.gov

Leuplin SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

Takeda·observational·Posted Jun 3, 2014·Updated Feb 17, 2016

In Brief

An observational study evaluating Leuprorelin acetate for Breast Cancer. Completed, enrolled 651 participants.

Detailed Summary

The purpose of this survey is to examine the safety and efficacy of long-term use (96 weeks) of leuprorelin acetate SR (slow release) 11.25 milligram (mg) for injection (Leuplin SR 11.25 mg for Injection) in premenopausal breast cancer patients in daily medical practice, as well as to examine factors that can influence the safety and efficacy of treatment with leuprorelin acetate SR 11.25 mg for injection (Leuplin SR 11.25 mg for Injection).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2014
Enrollment StartDec 1, 2005
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.1 years ago

Interventions

Leuprorelin acetatedrug

Leuprorelin acetate SR 11.25 mg for injection